Please login to the form below

Sosei Heptares

This page shows the latest Sosei Heptares news and features for those working in and with pharma, biotech and healthcare.

Genentech taps into Sosei Heptares GPCR expertise with $1bn alliance

Targeting largest family of proteins in cell membranes. Sosei Heptares has enticed another big biopharma company to sign up to its G-protein coupled receptor (GPCR) drug discovery platform. ... Sosei Heptares has developed considerable expertise in GPCRs

Latest news

Pfizer’s alliance with Sosei Heptares bears first fruit

The specific targets remain under wraps for now, although Sosei Heptares says they address metabolic and inflammatory diseases. ... The company was officially rebranded Sosei Heptares last December, but is still operating largely independently as a wholly
Tox trouble stalls Sosei/Allergan Alzheimer’s drug

The drug is one of the lead candidate from a $3.35bn licensing deal Allergan agreed with Sosei’s Heptares Pharma subsidiary two years ago, covering global rights to a portfolio ... We were very surprised to see these results given the safety profile
Pfizer signs high-level deal with GPCR specialist Heptares

Pfizer's strategic-level deal with Sosei subsidiary Heptares will see the UK firm apply its technologies to engineer stabilised target GPCR proteins - selected by Pfizer - that will be used to ... biologics drugs - and will pay up to $189m per project to
Teva buys into Heptares oral CGRP programme for migraine

Signs$410m alliance for early-stage candidates in potentially-lucrative drug class. Teva will co-develop Heptares Pharma's portfolio of migraine therapies in a new alliance valued at up to $410m. ... UK-based Heptares - which was acquired by Japan's

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Where next in Alzheimer’s disease R&D?

Whereas in the past the sector had “a very singular focus on amyloid”, Sosei Heptares’ chief R&D officer Malcolm Weir said he now thinks it is looking at targets “in ... Other groups, including Sosei Heptares, are working on novel ways to modify
Deal Watch March 2017

rights to Heptares’ G protein-coupled receptor product for pain relief. ... 20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.
Pharma deals in August 2015

Not disclosed. Staying in oncology, AstraZeneca closed an exclusive global licence with Heptares [owned by Sosei] securing a headline value of $510m. ... Acquisition–asset. 570. Heptares [Sosei]. AZ. HTL 1071 immuno‐oncology small molecule and other
Medius Deal Watch table for February 2015

Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.

More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest appointments

Metrion Biosciences adds to its board

Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Events Executive: DOE

Account Director – UK Office: Excellent salary and benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Manager – Healthcare advertising: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...